Nitric oxide regulates human eosinophil adhesion mechanismsin vitroby changing integrin expression and activity on the eosinophil cell surface

Open Access
Publisher Website
Google Scholar
Abstract
The nitric oxide synthase (NOS) inhibitor, Nω‐nitro‐L‐arginine methyl ester (L‐NAME), inhibits both rat and human eosinophil chemotaxis in vitro. Here, the role of nitric oxide (NO) in human eosinophil cell surface integrin expression and function was investigated. Human peripheral blood eosinophils were treated with L‐NAME (0.01 – 1.0 mM) and their adhesion to human fibronectin and serum observed. Adhesion of cells to fibronectin and serum increased by 24.0±4.6 and 43.8±4.7%, respectively, when eosinophils were treated with 1.0 mM L‐NAME. Increased adhesion by L‐NAME could be abolished when cells were co‐incubated with VLA‐4‐ and Mac‐1‐specific monoclonal antibodies (mAbs). The NO donor, sodium nitroprusside (2.5 mM), significantly inhibited eosinophil adhesion to fibronectin and serum by 34.3±4.5 and 45.2±5.6%, respectively. This inhibition was accompanied by a 4 fold increase in the levels of intracellular cyclic GMP. Flow cytometrical analysis demonstrated that L‐NAME induced an increased expression of CD11b (Mac‐1) on the eosinophil cell surface of 36.3±7.4%. L‐NAME had no effect upon CD49d (VLA‐4) expression. Treatment of human eosinophils, in vitro, with H‐[1,2,4] oxadiazolo quinoxalin‐1‐one (ODQ) (0.1 mM), an inhibitor of soluble guanylate cyclase, also significantly increased eosinophil adhesion to fibronectin and serum by 73.5±17.9 and 91.7±12.9%, respectively. This increase in adhesion could also be inhibited by co‐incubation with the Mac‐1 and VLA‐4‐specific mAbs. In conclusion, results indicate that NO, via a cyclic GMP‐dependent mechanism, inhibits the adhesion of human eosinophils to the extracellular matrix (ECM). This inhibition is accompanied by a decrease in the expression and function of the eosinophil's adhesion molecules, in particular, the expression of the Mac‐1 integrin and the function of the VLA‐4 integrin. British Journal of Pharmacology (2001) 134, 632–638; doi:10.1038/sj.bjp.0704295